The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function

1999/10/01 by Jesse M. Cedarbaum, Nancy Stambler, Errol Malta +4 · 3,317 citations
Medicine · Psychology · #Amyotrophic Lateral Sclerosis Research #Amyotrophic lateral sclerosis #Disease #Internal medicine #Medicine #Neurogenetic and Muscular Disorders Research #Physical medicine and rehabilitation #Physical therapy #Psychology #Quality of life (healthcare) #Rating scale

paper · doi:10.1016/s0022-510x(99)00210-5

published in Journal of the Neurological Sciences 169(1-2), 13-21 (Elsevier BV)

openalex publication_date 1999/10/01 · openalex created_date 2016/06/24 · openalex updated_date 2026/08/05

Cited by

• An observational study on quality of life and preferences to sustain life in locked-in state
• Independent home use of a brain-computer interface by people with amyotrophic lateral sclerosis
• Network spreading and local biological vulnerability in amyotrophic lateral sclerosis
• Developing a speech-based surface electromyography paradigm for automated objective assessment of bulbar involvement in amyotrophic lateral sclerosis: Considerations of task effects on motor and cognitive-linguistic functions
• Homecare amyotrophic lateral sclerosis (ALS): A multidisciplinary, home‐based model of care for patients with ALS and their caregivers
• Safety and effectiveness of risdiplam in adults with spinal muscular atrophy: a systematic review
• Using latent representations to link disjoint longitudinal data for mixed-effects regression
• A systematic review and meta-analysis of OCT-based ophthalmic changes in amyotrophic lateral sclerosis
• The challenge of controlling an auditory BCI in the case of severe motor disability
• Motor phenotypes and neurofilament light chain in genetic amyotrophic lateral sclerosis—results from a multicenter screening program
• Cognitive capacity in amyotrophic lateral sclerosis: the value of diagnostic markers in cerebrospinal fluid and the influence of nutrition and pulmonary function
• Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs
• Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in SOD1‐related ALS: Treatment experience in clinical practice
• Dextromethorphan/quinidine (DMQ) for reducing bulbar symptoms in amyotrophic lateral sclerosis – assessment of treatment experience in a multicenter study
• Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS
• Movement-related beta modulation in amyotrophic lateral sclerosis depends on muscle strength: A magnetoencephalography study
• Radiologically Inserted Gastrostomy Tube Placement Guided by the Assessment and Primary Palliative Care Provided by an Amyotrophic Lateral Sclerosis Multidisciplinary Clinic: A Single-Arm Retrospective Clinical Study
• Effects of non-invasive ventilation on objective sleep and nocturnal respiration in patients with amyotrophic lateral sclerosis
• Articulatory Kinematic Characteristics Across the Dysarthria Severity Spectrum in Individuals With Amyotrophic Lateral Sclerosis
• A meaningful prediction of functional decline in amyotrophic lateral sclerosis based on multi-event survival analysis
• Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis
• Inter-speaker acoustic differences of sustained vowels at varied dysarthria severities for amyotrophic lateral sclerosis
• Alterations of T cell subsets in ALS: a systemic immune activation?
• Abundant FUS-immunoreactive pathology in the skin of sporadic amyotrophic lateral sclerosis
• Toward in vivo determination of peripheral nervous system immune activity in amyotrophic lateral sclerosis
• Living Will and Advance Care Planning in Patients With Amyotrophic Lateral Sclerosis Admitted to Specialistic Home Palliative Care
• Phase I clinical trial of safety of L-serine for ALS patients
• Inclusion body myositis functional rating scale: A reliable and valid measure of disease severity
• Ectopic impulse generation in peripheral nerve hyperexcitability syndromes and amyotrophic lateral sclerosis
• Safety and activity of anti‐CD14 antibody IC14 (atibuclimab) in ALS: Experience with expanded access protocol
• Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression
• Neurofilaments as Biomarkers for Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis
• Prevalence of depressive disorders and change over time in late-stage ALS. [europepmc]
• Widespread sensorimotor and frontal cortical atrophy in Amyotrophic Lateral Sclerosis. [europepmc]
• Social uses of personal health information within PatientsLikeMe, an online patient community: what can happen when patients have access to one another's data. [europepmc]
• Oxidative stress biomarkers in sporadic ALS. [europepmc]
• Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS). [europepmc]
• Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. [europepmc]
• Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. [europepmc]
• Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. [europepmc]
• Pattern of ubiquilin pathology in ALS and FTLD indicates presence of C9ORF72 hexanucleotide expansion. [europepmc]
• Controversies and priorities in amyotrophic lateral sclerosis. [europepmc]
• Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. [europepmc]
• The Communicative Participation Item Bank (CPIB): item bank calibration and development of a disorder-generic short form. [europepmc]
• TDP-43 pathology and neuronal loss in amyotrophic lateral sclerosis spinal cord. [europepmc]
• Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. [europepmc]
• Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. [europepmc]
• Association of Regulatory T-Cell Expansion With Progression of Amyotrophic Lateral Sclerosis: A Study of Humans and a Transgenic Mouse Model. [europepmc]
• Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. [europepmc]
• Hypermetabolism in ALS is associated with greater functional decline and shorter survival. [europepmc]
• ALS-specific cognitive and behavior changes associated with advancing disease stage in ALS. [europepmc]
• ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? [europepmc]
• SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS. [europepmc]
• Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. [europepmc]
• Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. [europepmc]
• Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. [europepmc]
• Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS. [europepmc]